Supplemental Digital Content 4: Proportion of Patients with a) sub-retinal fluid, b) intra-retinal edema, c) intra-retinal cysts, and d) CNV leakage from baseline to Month 12 (Full analysis set* [modified last observation carried forward])

a.
b.

![Bar chart showing the proportion of patients with intra-retinal edema at different time points.]

- **Baseline**: 86.8%, 88%, 81.3%
- **Month 3**: 43.4%, 45.1%, 65.9%
- **Month 6**: 37.4%, 33.7%, 50.5%
- **Month 12**: 28%, 23.4%, 28.6%

Legend:
- Ranibizumab 0.5 mg (VA stabilization; Group I) (n = 182)
- Ranibizumab 0.5 mg (disease activity; Group II) (n = 184)
- vPDT (Group III) (n = 91)

Presence of intra-retinal edema
d.

- Ranibizumab 0.5 mg (VA stabilization; Group I) (n = 182)
- Ranibizumab 0.5 mg (disease activity; Group II) (n = 184)
- vPDT (Group III) (n = 91)

*Consisted of all patients to whom study treatment were assigned.

VA, visual acuity; vPDT, verteporfin photodynamic therapy